Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Catalyst Pharm Inc (CPRX)

Catalyst Pharm Inc (CPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses GlobeNewswire - Tue Jun 30, 7:03AM CDT

CORAL GABLES, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and...

CPRX : 31.45 (+0.03%)
Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders? PR Newswire - Thu Jun 25, 12:56PM CDT

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

TMHC : 71.86 (+0.18%)
NUVL : 123.73 (+0.11%)
CPRX : 31.45 (+0.03%)
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX Business Wire - Wed Jun 24, 1:38PM CDT

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Catalyst Pharmaceuticals...

CPRX : 31.45 (+0.03%)
Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders? PR Newswire - Tue May 19, 5:22PM CDT

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

KALV : 27.00 (+0.04%)
CPRX : 31.45 (+0.03%)
MDV : 17.89 (+2.82%)
GBTG : 9.40 (unch)
Are CPRX, UNF, RMAX, ACR Obtaining Fair Deals for their Shareholders? PR Newswire - Tue May 12, 1:56AM CDT

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

ACR : 18.00 (-0.50%)
RMAX : 11.12 (+6.51%)
CPRX : 31.45 (+0.03%)
UNF : 273.56 (+2.63%)
Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results GlobeNewswire - Mon May 11, 3:12PM CDT

Delivered Q1 2026 Total Revenues  of $149.4 Million Results include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million...

CPRX : 31.45 (+0.03%)
CPRX's Rare Disease Portfolio May Finally Be Too Concentrated for Comfort Barchart - Sun May 10, 4:00PM CDT

Barchart Research What to Expect from CPRX Earnings CPRX Generated May 8, 2026 Current Price $31.15 EPS Estimate $$0.58 Consensus Rating Strong Buy Average Move 5.18% CPRX's Rare Disease Portfolio May...

CPRX : 31.45 (+0.03%)
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX Business Wire - Sat May 9, 7:21PM CDT

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Catalyst Pharmaceuticals...

CPRX : 31.45 (+0.03%)
CPRX's Rare Disease Portfolio May Finally Be Too Concentrated for Comfort Barchart - Sat May 9, 4:00PM CDT

Barchart Research What to Expect from CPRX Earnings CPRX Generated May 8, 2026 Current Price $31.15 EPS Estimate $$0.58 Consensus Rating Strong Buy Average Move 5.18% CPRX's Rare Disease Portfolio May...

CPRX : 31.45 (+0.03%)
Are CPRX, TBRG, MDV, ACR Obtaining Fair Deals for their Shareholders? PR Newswire - Fri May 8, 4:56PM CDT

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

ACR : 18.00 (-0.50%)
TBRG : 26.24 (+0.04%)
CPRX : 31.45 (+0.03%)
MDV : 17.89 (+2.82%)

Barchart Exclusives

Nike Beat Wall Street Estimates by a Mile. Why Investors Are Still Not Convinced. Barchart - Thu Jul 2, 6:30PM CDT
Nike crushed Wall Street's expectations, but investors remain focused on a turnaround that is still far from complete. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.